SCHEMBL233497

SCHEMBL233497

Clc1ccccc1Cc1cnc(NNc2ncc(Cc3ccccc3Cl)o2)o1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
ALDH1A1 P00352 2/20 0.37
PKM P14618 1/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
CFTR P13569 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ABL1 P00519 1/20 0.36
PNMT P11086 1/20 0.36
IDO1 P14902 1/20 0.36
NLRP3 Q96P20 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
PTK2 Q05397 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2754086 0.80 KDM4E (0.47) POLBALDH1A1KMT2AMEN1CFTR
SCHEMBL233496 0.79 PNMT (0.41) POLBTAAR1ABL1PNMTIDO1
SCHEMBL2199821 0.79 PNMT (0.41) POLBTAAR1ABL1PNMTIDO1
SCHEMBL2754033 0.78 HDAC3 (0.44) ALDH1A1KMT2AMEN1CFTRHDAC3
SCHEMBL2754083 0.75 CFTR (0.54) POLBALDH1A1PKMKMT2AMEN1
SCHEMBL2753930 0.75 CFTR (0.49) POLBALDH1A1PKMKMT2AMEN1
SCHEMBL2752649 0.73 KCNQ2 (0.54) POLBALDH1A1KMT2AMEN1CFTR
SCHEMBL235295 0.73 LMNA (0.44) TAAR1KMT2AMEN1KDM4EABL1
SCHEMBL2753929 0.73 P2RX7 (0.47) POLBALDH1A1PKMKMT2AMEN1
SCHEMBL672407 0.67 IDO1 (0.62) TAAR1PKMPNMTIDO1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9550761-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-01-24 US disclosed
US-9249131-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-02-02 US disclosed
US-20150025076-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2015-01-22 US disclosed
US-20120004216-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-05 US disclosed
US-7973169-B2 including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), such as N-(4,5-Diphenyl-thiazol-2-yl)-benzamide, used for treating genetic disorders; respiratory system disorders VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-05 US disclosed
EP-1664006-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2006-06-07 EP disclosed
US-20050176789-A1 Modulators of ATP-Binding Cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2005-08-11 US disclosed
WO-2005026137-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176789-A1 Modulators of ATP-Binding Cassette transporters CFTR, ABCB1, ABCF1 POLB 1440/4885TAAR1 3317/4885ALDH1A1 2247/4885
US-20120004216-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCF1 POLB 1440/4885TAAR1 3317/4885ALDH1A1 2247/4885
US-20150025076-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCF1 POLB 1494/4885TAAR1 3287/4885ALDH1A1 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.